Interaction of nonpeptidic δ agonists with P-glycoprotein by in situ mouse brain perfusion:: Liquid chromatography-mass spectrometry analysis and internal standard strategy

Many opioids are substrates of the efflux transporter P-glycoprotein (P-gp) in the blood-brain barrier (BBB). In situ brain perfusion in wild-type and mdr lalpha(-/-) P-gp-deficient mice was utilized to investigate potential P-gp-mediated transport of novel nonpeptidic delta agonists (AR-M delta compounds). Because radioactive compounds were not available for this series, liquid chromatography-mass spectrometric detection (LCMS) was the assay methodology of choice. Verapamil in the perfusion buffer (0.5 muM) served as a positive control for P-gp-mediated efflux and as an experimental internal standard for P-gp modulation by AR-M delta compounds. LC-MS provided excellent assay sensitivity with no significant interferences. In P-gp-competent mice, the brain extraction of AR-M delta compounds ranged from 1.1 to 96%. The ratio of initial brain uptake clearances (Cl-up) in P-gp-deficient and wild-type mice (P-gp effect) ranged from 0.96 to 4.91. Some compounds increased the Cl-up of verapamil in P-gp-competent mice, consistent with P-gp inhibition. These results demonstrate that LC-MS is an appropriate assay methodology for mouse brain perfusion samples, that AR-M delta compounds may interact with P-gp in the BBB, and that the internal strategy can provide useful information concerning P-gp modulation by compounds of interest. (C) 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association.